for the Period Ended 31 July 2023
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 July 2023
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 August 2022 to 31 July 2023
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2023 | 2022 | |
---|---|---|
| £ | £ |
Turnover: | | |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Operating profit(or loss): | | |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
As at
Notes | 2023 | 2022 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 3 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Members' funds | |||
Profit and loss account: | | | |
Total members' funds: | | |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 July 2023
Basis of measurement and preparation
Turnover policy
Other accounting policies
for the Period Ended 31 July 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 July 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Taxation and social security | | |
Other creditors | | |
Total | | |
iDEAL Diabetes CIC enables the delivery of best practice in diabetes care for every person living with diabetes. Having identified gaps in care and support provided to people living with and at risk of diabetes, it provides practical tools and position papers on key topics around diabetes care to health care professionals, people with diabetes and the community.During the financial year ending 31st June 2023 the activities carried out by iDEAL have benefitted health care professionals, people with diabetes and the community in the following ways:Across the UK and globally, healthcare professionals and people with diabetes have had access to a simple and effective system to identify early warning signs for diabetes related foot issues and how to seek help as required.. We promoted better understanding of when to access emergency care to help to prevent amputations. We have developed new webpages and resources for health care professionals professionals related to periodontitis, sexual dysfunction and have created three Best Practice Guides. Through our substantive engagement with stakeholder organisations, such as Diabetes UK and the Primary Care Diabetes Society we have extended our reach to both healthcare professionals and patients.
Ideal has regular contact with its key stakeholders, these being people with and at risk of diabetes and the healthcare professionals that provide care for them. The company’s directors are representatives of both. Our advisory group includes senior representatives of Diabetes UK, the Primary Care Diabetes Society, The British Dietetic Association, as well as numerous leading academic and clinical institutions. In shaping each piece of work we undertake, we have engaged with these and other organisations, including the Juvenile Diabetes Research Foundation, Diabetes Wellness and Research Foundation, local patient groups across the UK, NHS England, the International Diabetes Federation, D-Foot International.
The aggregate amount of emoluments paid to or receivable by directors in respect of qualifying services was £18,550.There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed.
No transfer of assets other than for full consideration
This report was approved by the board of directors on
1 March 2024
And signed on behalf of the board by:
Name: John Grumitt
Status: Director